COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,672 Articles (22,913 medRxiv, 8,759 bioRxiv)

Most recent first Previous |  Page 1032: Articles 10311-10320  | Next

COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron
Suntronwong, N., Yorsaeng, R., Puenpa, J., Auphimai, C., Thongmee, T., Vichaiwattana, P., Kanokudom, S., Duangchinda, T., Chantima, W., Pakchotanon, P., Assawakosri, S., Nilyanimit, P., Klinfueng, S., Wongsrisang, L., Srimuan, D., Thatsanatorn, T., Sudhinaraset, N., Wanlapakorn, N., Poovorawan, Y.
10.1101/2022.01.17.22269415 — Posted: 2022-01-18
Detection of SARS-CoV-2 variant Mu, Beta, Gamma, Lambda, Delta, Alpha, and Omicron in wastewater settled solids using mutation-specific assays is associated with regional detection of variants in clinical samples
Wolfe, M., Hughes, B., Duong, D., Chan-Herur, V., Wigginton, K. R., White, B., Boehm, A. B.
10.1101/2022.01.17.22269439 — Posted: 2022-01-18
Understanding Evolution of COVID-19 Driven Mortality Rate
Bhaumik, I., Ray, S. S., Chaudhary, A., Srivastava, A., Kodgire, P.
10.1101/2022.01.16.22269210 — Posted: 2022-01-18
OMICRON-ASSOCIATED CHANGES IN SARS-COV-2 SYMPTOMS IN THE UNITED KINGDOM
Vihta, K.-D., Pouwels, K. B., Peto, T. E., Pritchard, E., House, T., Studley, R., Rourke, E., Cook, D., Diamond, I., Crook, D., Matthews, P. C., Stoesser, N., Eyre, D. W., Walker, A. S., COVID-19 Infection Survey team
10.1101/2022.01.18.22269082 — Posted: 2022-01-18
The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant
Hogan, A. M., Wu, S. L., Doohan, P., Watson, O. J., Winskill, P., Charles, G., Barnsley, G., Riley, E. M., Khoury, D. S., Ferguson, N. M., Ghani, A.
10.1101/2022.01.17.22269222 — Posted: 2022-01-18
Estimation of the COVID-19 Average Incubation Time:Systematic Review, Meta-analysis and SensitivityAnalyses
Weng, Y., Yi, G. Y.
10.1101/2022.01.17.22269421 — Posted: 2022-01-18
Non-Communicable Diseases Risk Factors and the Risk of COVID-19 Infection among University Employees in Indonesia
Widyahening, I. S., Vidiawati, D., Pakasi, T. A., Soewondo, P., Ahsan, A.
10.1101/2022.01.17.22269249 — Posted: 2022-01-18
SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients.
Charvet, B., Brunel, J., Pierquin, J., Iampietro, M., Decimo, D., Queruel, N., Lucas, A., del Mar Encabo-Berzosa, M., Arenaz, I., Perez Marmolejo, T., Valezka Bolanos Morales, F., Ivan Gonzalez Gonzalez, A., Castorena Maldonado, A., Luna Rivero, C., Mathieu, C., Kury, P., Flores-Rivera, J., Avila Rios, S., Salgado Montes de Oca, G., Schoorlemmer, J., Horvat, B., Perron, H. J.
10.1101/2022.01.18.21266111 — Posted: 2022-01-18 Discussion: Onsite
Booster vaccination to curtail COVID-19 resurgence - population-level implications of the Israeli campaign
Gavish, N., Yaari, R., Huppert, A., Katriel, G.
10.1101/2022.01.18.22269141 — Posted: 2022-01-18
Effectiveness of mRNA COVID-19 Vaccines against Omicron among Veterans
Young-Xu, Y.
10.1101/2022.01.15.22269360 — Posted: 2022-01-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).